Caxton Associates (New York)’s PRA Health Sciences, Inc. PRAH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-8,025
Closed -$1.33M 650
2021
Q2
$1.33M Buy
+8,025
New +$1.34M 0.15% 51
2020
Q4
Sell
-3,807
Closed -$386K 370
2020
Q3
$386K Sell
3,807
-312
-8% -$31.8K 0.04% 148
2020
Q2
$401K Buy
+4,119
New +$383K 0.04% 180
2020
Q1
Sell
-1,925
Closed -$214K 646
2019
Q4
$214K Buy
+1,925
New +$198K 0.03% 345
2019
Q2
Sell
-5,133
Closed -$566K 567
2019
Q1
$566K Buy
+5,133
New +$536K 0.08% 127
2018
Q4
Sell
-6,892
Closed -$759K 516
2018
Q3
$759K Buy
+6,892
New +$718K 0.05% 176
2018
Q2
Sell
-6,650
Closed -$552K 507
2018
Q1
$552K Sell
6,650
-4,654
-41% -$414K 0.03% 250
2017
Q4
$1.03M Buy
11,304
+5,004
+79% +$416K 0.05% 206
2017
Q3
$480K Hold
6,300
0.02% 351
2017
Q2
$473K Buy
+6,300
New +$437K 0.02% 359

Other funds holding PRAH

Caxton Associates (New York)'s PRAH Position: Q3 2021 in Review

Caxton Associates (New York) sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 8,025 shares — an estimated $1.33M sold.

Caxton Associates (New York) first reported a position in PRAH in Q2 2017 and held it in 10 quarters. The position peaked at $1.33M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.

  • Caxton Associates (New York) reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Caxton Associates (New York) sold 8,025 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $1.33M.
  • Caxton Associates (New York) first reported a position in PRA Health Sciences, Inc. in Q2 2017 and held it in 10 quarters.
  • Caxton Associates (New York)'s PRA Health Sciences, Inc. position peaked at $1.33M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.

Based on Caxton Associates (New York)'s 13F filing for Q3 2021, filed 15 Nov 2021.